Skip to main content
. 2000 Oct 3;97(21):11256–11261. doi: 10.1073/pnas.190353897

Figure 3.

Figure 3

Mutations of BRCA1 reduce the enhancement of AR transactivation. PC-3 cells in 35-mm dishes were cotransfected with 0.5 μg of reporter plasmid MMTV-LUC, 0.5 μg of pSG5AR, and 1 μg of BRCA1 construct for 2 h. 1 nM DHT was then added for 24 h before cells were harvested for LUC assay. As compared with the wild-type BRCA1, the cotransfection of three mutant BRCA1s, one of the constructs lacks the C terminus of BRCA1 (BRCA1 amino acids 1–772), one has a point mutation at its C terminus (BRCA1-P1749R), and the other lacks exon 11 (BRCA1-Δ11), reducing the enhancement of AR activity (lane 3 vs. lanes 4–6).